Every material Form 8-K Climb Bio, Inc. has filed with the SEC since October 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Climb Bio reported a third-quarter 2026 net loss of $14.6 million, up from $12.9 million a year earlier, as R&D spending rose to $11.0 million. Net loss per share narrowed to $0.18 from $0.19, and the company said its $227.6 million cash position funds operations into the second half of 2028. The filing also updated clinical programs for budoprutug and CLYM116, including dosing in a Phase 2 trial and additional data expected in 2027.
Q3 2026 net loss was $14.6 million versus $12.9 million in Q3 2025; net loss per share was $0.18 versus $0.19.
R&D expenses rose to $11.0 million from $9.1 million; G&A was flat at $5.8 million.
Cash, cash equivalents and marketable securities were $227.6 million as of September 30, 2026, with runway expected into the second half of 2028.
CLYM116 NAVIGATE-2 Phase 2 trial in IgA nephropathy began dosing, with initial data expected in the first half of 2027.
Climb Bio presented initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026, with the 200 mg cohort showing B-cell depletion, PLA2R antibody reduction and immunologic remission at Week 12. The results were consistent with Phase 1b data, and the 600 mg cohort showed greater drug exposure and deeper B-cell suppression at Week 4, but the cohorts are small and follow-up is limited, and the company expects additional Phase 2 data in 2027.
200 mg cohort: mean PLA2R antibody reduction of 70% at Week 12; five of 13 patients (38%) achieved immunologic remission
Patients with baseline PLA2R antibody levels below 175 RU/mL had a mean reduction of 80% at Week 12
600 mg cohort: mean peripheral CD20+ B-cell suppression of 98% at Week 4, compared with 74% at 200 mg
Budoprutug was generally well tolerated in the 200 mg and 600 mg cohorts; no treatment-related serious adverse events were reported
Climb Bio and Mabworks reported additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, presented at ASN Kidney Week 2026. The data show an estimated half-life of about 33 days and, at 12 weeks after an 800 mg dose, reductions of about 70% in Gd-IgA1 and about 60% in IgA. The filing contains no revenue or earnings figures, and the next key milestone remains initial data from the NAVIGATE-2 Phase 2 trial in the first half of 2027.
Estimated half-life of approximately 33 days, based on the 800 mg and 320 mg multiple-ascending dose cohorts
Free APRIL suppression of 90% or more through 12 weeks after a single subcutaneous dose of 480 mg or higher
About 70% Gd-IgA1 and about 60% IgA reduction at 12 weeks after a single 800 mg dose, the NAVIGATE-2 loading dose
Injection site reactions in 5 of 88 participants, all Grade 1; initial NAVIGATE-2 data expected in the first half of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Climb Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →